Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - October 2012


Pharma Commercial Excellence in CEE, CIS, SEE & Turkey

04 Oct 2012 - 05 Oct 2012 - Budapest, Hungary



Bookmark and Share


At this 2-day event attendees will have a unique chance to interact with the pharmaceutical specialists from concerned regions. The representatives from AstraZeneca, Sanofi, Merck, Novartis, Teva etc. will share their best practices in the form of presentations and case studies. 

During the 2-stream program on both days, 20 experts speakers will provide participants with governmental perspective, industry and regulatory insights, and physicians' and payers' perspectives. 

The special block, involved into the first conference day, will bring the deeper insight into the HTA processes throughout the regions. Russian, Slovak, Serbian, Polish, Swedish and Turkish perspectives will be introduced.

How to maintain and maximize competitive advantage in the region? How to optimize interactions between the key stakeholders? What are the ways to predict and meet customer needs? These are only few of many questions that will be answered at Fleming Europe's conference.

For more information request the detailed agenda http://pharma.flemingeurope.com/pharma-excellence/request-agenda




Further information
Scientific News
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!